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To The ediTor:
Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is 
an uncommon disease of the pleura and lungs. In 2013, 
IPPFE was classified as a rare interstitial lung disease 
(ILD) in a joint American Thoracic Society/European 
Respiratory Society statement on the classification of 
the idiopathic interstitial pneumonias.(1) Characterized 
by fibrosis, together with thickening of the pleural and 
subpleural tissue (subpleural fibroelastosis), IPPFE 
predominantly affects the periphery of the upper lung 
lobes, with volume loss, as first described by Frankel et 
al. in 2004. (2) To date, no more than forty cases of IPPFE 
have been described in the literature in English. There is 
currently no consensus regarding the diagnostic criteria 
used in order to classify IPPFE, as well as regarding whether 
or not it represents a real, new, specific entity. Although 
the etiology is unknown, conditions associated with the 
disease include infections, bone marrow transplantation, 
autoimmunity, and possibly genetic predisposition. 
Clinically, patients with IPPFE usually present with chronic 
respiratory symptoms such as dyspnea and dry cough. 
The diagnosis of IPPFE is established on the basis of 
clinical, radiological, and histopathological findings. Chest 
HRCT scans show marked subpleural consolidations with 
irregular thickening; distortion, usually located in upper 
lung lobes (“pleural cap”); subpleural bronchiolectasis; 
reticular opacities; and, in some cases, mild honeycombing. 
These features are similar to those of other forms of 
idiopathic pulmonary fibrosis. However, in IPPFE, they 
are seen mainly in upper lobes, being rare or absent in 
the lower lobes.(3,4) The histological characteristics of 
IPPFE are homogeneous subpleural fibrosis and abundant 
elastic fibers on elastic fiber stains.(5) 
A 55-year-old nonsmoking female presented to her 
pulmonologist with fever (38°C for six days), worsening 
of dyspnea under stress, and a productive cough. The 
patient stated that she had not been previously exposed 
to environmental allergens or asbestos. She further 
stated that she had not used any drugs and had not 
been previously exposed to environmental allergens, 
as well as that she had not been under treatment with 
chemotherapy or radiotherapy. She tested positive only 
for autoantibodies against endomysium; other serological 
tests were negative. Physical examination showed that, 
over a period of six months, she had lost weight (5 kg) 
and muscle mass. There was also a reduction in oxygen 
saturation (SaO2 of 81% on room air). On auscultation, 
there were reduced breath sounds and mild bilateral 
rales in the upper lung fields. Heart rate and rhythm 
were normal. Her extremities were also normal, without 
digital clubbing. Pulmonary function tests showed 
normal FVC (96%) and normal FEV1 (91%), although 
the DLCO was reduced (61%). An initial chest X-ray 
(not shown) revealed marked, irregular opacities in the 
subpleural region of the upper fields, with mild upper 
hilar retraction. Fiberoptic bronchoscopy with BAL was 
carried out, and neutrophils were found to account for 
72% of the inflammatory cells (normal value, 1-2%). 
Microbiology tests were negative. To elucidate the chest 
X-ray and BAL findings, we performed chest HRCT. The 
HRCT scans showed peripheral foci of lung consolidation, 
with distortion and irregular pleuroparenchymal thick-
ening, that was most evident in the subpleural regions 
of the upper lobes, accompanied by bronchiolectasis, 
mild interlobular septal thickening, and (in rare cases) 
microcystic subpleural changes (Figure 1A). Scans of 
the lower lung fields (middle lobe and lingula) showed 
considerably fewer fibrotic changes, no distortion or 
other interstitial disease being observed in the apical 
and basal segments of the lower lobes (Figures 1B and 
1C, respectively). These HRCT characteristics pose a 
diagnostic dilemma for the radiologist, who must make 
the differential diagnosis among IPPFE, sarcoidosis, and 
(albeit less likely) chronic hypersensitivity pneumonia. 
Therefore, we also performed a pleuroparenchymal frozen 
section biopsy in the upper lobes. Histopathological 
findings from elastic fiber staining revealed distortion 
and marked pleural thickening, with evidence of dense 
fibroelastotic tissue in the pleura and alveolar walls, 
together with sparse fibroblastic foci near the transition 
from the lung to the pleura (Figure 1D). On the basis of 
the clinical and radiological data, a diagnosis of IPPFE 
was made. In conclusion, although there are specific 
HRCT features that are suggestive of IPPFE, the disease 
continues to be underdiagnosed, probably because there 
is still a significant lack of knowledge and awareness of 
this entity. A diagnosis of IPPFE should be considered in 
cases of pulmonary fibrosis that is located predominantly 
in the upper lobes. The differential diagnosis includes 
advanced hypersensitivity pneumonia, advanced 
sarcoidosis, advanced smoking-related ILD, asbestosis, 
connective tissue disease, radiation pneumonia, and 
drug-induced lung disease. The possibility of IPPFE should 
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therefore be borne in mind when the radiological 
evidence is not consistent with other, more well-defined 
ILDs. It is recommended that surgical biopsy (using 
video-assisted thoracoscopic surgery)—or better yet 
frozen section biopsy—be performed in the affected 
area. A greater understanding of the etiology, risk 
factors, prognosis, and therapy related to IPPFE is 
needed in order to manage this disease in the future.
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Figure 1. Chest HRCT and histology: A) HRCT scan showing marked subpleural thickening and irregular consolidations 
(black arrows), reticular opacities in the lung parenchyma at upper lobes, microcystic subpleural changes (white arrows), 
and bronchiolectasis; B) HRCT scan showing sparse fibrotic subpleural changes in the apical segments of the lower lung 
lobes, most pronounced on the right; C) HRCT scan showing near absence of fibrotic changes in the basal segments of 
the lower lung lobes; and D) histological section showing dense subpleural fibroelastotic tissue with an abrupt transition 
from pathological to normal lung parenchyma, containing a fibroblastic focus.
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